Marshall Wace
EWTX icon

Marshall Wace’s Edgewise Therapeutics EWTX Stock Holding History

Marshall Wace’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.4M Sell
648,393
-33,528
-5% -$967K 0.02% 698
2025
Q4 		$16.9M Buy
+681,921
New +$13.7M 0.02% 685
2025
Q1 		– Sell
-29,893
Closed -$798K – 2753
2024
Q4 		$798K Sell
29,893
-547,672
-95% -$17.4M ﹤0.01% 1834
2024
Q3 		$15.4M Buy
577,565
+161,845
+39% +$3.22M 0.02% 597
2024
Q2 		$7.49M Buy
415,720
+361,103
+661% +$6.3M 0.01% 850
2024
Q1 		$996K Buy
+54,617
New +$868K ﹤0.01% 1652

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Marshall Wace's EWTX Position: Q1 2026 in Review

Marshall Wace reduced its Edgewise Therapeutics (EWTX) stake by 4.9% in Q1 2026, selling an estimated $967K and leaving 648,393 shares worth $20.4M. The position accounts for 0.02% of the portfolio, ranked #698.

Marshall Wace first reported a position in EWTX in Q1 2024 and has held it in 6 quarters since. 214 funds tracked by Wall St. Rank hold EWTX as of Q1 2026.

  • Marshall Wace held 648,393 shares of Edgewise Therapeutics worth $20.4M as of Q1 2026.
  • Marshall Wace sold 33,528 Edgewise Therapeutics shares in Q1 2026, an estimated $967K.
  • Edgewise Therapeutics made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #698 holding.
  • Marshall Wace first reported a position in Edgewise Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • 214 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.